Introduction
Neoadjuvant chemotherapy, or rounds of chemotherapy given prior to tumor excision, has been in widespread use in osteosarcoma patients since its efficacy was demonstrated by Rosen et al. and Winkler et al. in 1979 and 1984, respectively [1, 2] . Methotrexate, adriamycin (doxorubicin), and cis-platin (the MAP regimen) is the current standard of care for osteosarcoma. The MAP regimen as neoadjuvant chemotherapy has yielded substantial improvements in patient morbidity and mortality since its widespread acceptance nearly thirty years ago. Additionally, the prognostic value of response to neoadjuvant chemotherapy, assessed by tumor necrosis grading at the time of tumor resection, has been shown [3, 4] . Thus, tumor response to initial rounds of chemotherapy is indicative of patient outcome. Despite these findings, trials which have attempted to exploit the prognostic value of response to neoadjuvant chemotherapy in osteosarcoma have not yet reported significant improvement in outcomes [5] . Non-responsive tumors frequently acquire increased expression of the ATP-binding cassette (ABC) family of efflux transporters, which reduce the intracellular concentration of chemotherapy toxins such as paclitaxel, 5-fluorouracil, etoposide, olaparib, and doxorubicin (dox) by limiting their intracellular concentrations [6] [7] [8] . In multiple cancers, several ABC transporters have been shown to facilitate the efflux of dox, including ABC3, MDR1, MDR3, ABC19, MRP1, MRP2, MRP6, and BCRP1 [8] [9] [10] [11] [12] . Overlapping selectivity between chemotherapies and ABC transporters is reported, thus dox-resistance through cellular efflux is driven by a multi-modal and adaptable system which generally produces the multidrug resistance (MDR) phenotype. In this manner, acquired resistance to one chemotherapy (such as dox) through ABC overexpression, is reported to confer resistance to other anticancer chemotherapies which are also ABC substrates [7] . This mechanism of resistance is associated with poor outcomes in various human cancers [6] [7] [8] .
Recently, inhibitors of the canonical Wnt signaling pathway have been explored as chemotherapy sensitizing agents in lung and colorectal cancer models. In these studies, inhibitors of the Axin2-regulating Tankyrase 1 and Tankyrase 2 enzymes (Tnks1/2) have been shown to sensitize to epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase (PI3K), and AKT inhibition in various cancer models [13] [14] [15] [16] DNA damage. Moreover, regulation of ABC transporter expression by β-catenin, the primary target of canonical Wnt signaling, has been reported, indicating that transcriptional regulation of the ABC transporters through Wnt inhibition may be possible [17] [18] [19] . Thus, we sought to investigate the ability of Tnks1/2 inhibition, via the small molecule Tnks1/2 inhibitor IWR-1-endo (IWR-1), to mitigate resistance to dox in osteosarcoma. We developed a model of chemotherapy resistant osteosarcoma by challenging a naïve cell line with dox, selecting surviving colonies, and expanding the resistant cells for further challenge. Treatment of chemotherapy-resistant osteosarcoma cells with IWR-1 significantly increased intracellular concentrations of Calcein AM and doxorubicin in resistant cells, indicating inhibition of cellular efflux transport. This effect was observed to be independent of regulation of Wnt target genes. Dox-resistant cells were sensitized by pre-treatment with IWR-1, causing increased toxicity from dox and accumulation of cells at the G2/M checkpoint. Additionally, our data show increased numbers of γH2AX foci with IWR-1 sensitization, indicating increased damage to DNA via accumulation of dox in the cell. In sum, we report that IWR-1 inhibits cellular efflux capacity, and sensitizes to dox in a model of chemotherapy resistant osteosarcoma.
Materials and methods

Mammalian cell culture
Human osteosarcoma cell lines 143b (143b-wt, American Type Culture Collection, Manassas, VA, USA), and the derived 143b doxorubicin-resistant cell line (143b-DxR) were cultured in 75 cm −2 flasks in Dulbecco's Advanced Modified Eagles Media-F12 (DMEM-F12, SigmaAldrich, St. Louis, MO, USA) formulation without the addition of penicillin or streptomycin. The 143b-DxR cell line was developed by challenge with doxorubicin (Sigma-Aldrich, St. Louis, MO, USA), and selection and expansion of colonies which were resistant to the drug. The 143b-DxR cell line was continuously kept in 200 nM doxorubicin.
Prior to use, cell lines were kept in liquid phase nitrogen.
mRNA expression quantitation
Trizol reagent (Invitrogen, Carlsbad, CA, USA) and the Zymo Quick-RNA™ MicroPrep kit (Zymo Research, Irvine, CA, USA) were used to collect and purify RNA from cells. cDNA was produced from 2.0 μg of RNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Fisher Scientific, Waltham, MA, USA). A 10 μL reaction volume containing a total of 25 ng of sample cDNA was used for each qRT-PCR reaction. qRT-PCR was performed on an ABI HT7000 Thermocycler using SYBR GreenER (Thermo-Fisher, Waltham, MA, USA). The quantitation of mRNAs has been carried out by normalizing the data using GAPDH as described in the manufacturer's protocol (Thermo-Fisher, Waltham, MA). Primer sequences used: GAPDH F 5′-ATGTTCGTCATGGGTGTGAA-3′, R 5′-TGTGGTCATGAGTCCTT CCA-3′; Axin2 F 5′-AGAAATGCATCGCAGTGTGAAG-3′, R 5′-GGGTTC TCGGGAAATGAGGTA-3′;
MDR-1F 5′-GAGCCCATCCTGTTTGAC TGC-3′, R 5′-TGTATGTTGGCCTCCTTTGCTG-3′.
Cytotoxicity assay
× 10
4 cells were plated per well in 24-well polystyrene dishes and allowed to adhere for 16 h before treatment with vehicle or drug. All treatment solutions were prepared in DMEM-F12 as described above without the addition of fetal bovine serum (Thermo-Fisher, Waltham, MA, USA), and incubated at 37°C for the entirety of the treatment. 
Dose-response curve fitting
The GraphPad Prism 7 software was used to perform non-linear fitting of the dose-response curves for excitation (Calcein AM or doxorubicin retention) and inhibition (doxorubicin toxicity) experiments. These models additionally provided the reported values for the E MAX , EC 50 , and IC 50 , where appropriate.
Cell cycle analysis
143b-wt or 143b-DxR cells were seeded onto 10 cm dishes at a density of 5x10 5 
Results
Expression of Wnt target genes Axin2 and MDR-1 was not reduced by IWR-1 treatment for 16 h in either the 143b-wt or the 143b-DxR cell lines (Fig. 1A) . Incubation with doxorubicin (dox) following IWR-1 treatment caused increased fluorescence from intracellular dox (Fig. 1B) . Significantly stronger fluorescent emission from doxorubicin was observed in the 143b-DxR cell line, compared to the 143b-wt cells. Treatment with IWR-1 for 16 h significantly stimulated fluorescent staining with Calcein AM in the 143b-DxR cell line, with no strong effect on the 143b-wt cells (Fig. 2A) . For comparison, and to evaluate the dynamic range of the assay, 143b-DxR and 143b-wt cells were treated with verapamil for 15 min, and intracellular Calcein AM fluorescence was measured (Fig. 2B) . The EC 50 values for IWR-1 and verapamil in the Calcein AM retention assays were 8.40 µM and 5.46 µM, respectively, as calculated from non-linear fitting of the dose response curves ( Table 1) .
The capacity for IWR-1 to act as an inhibitor of cellular efflux led us to hypothesize that these cell lines could be sensitized to the DNA damaging effects of dox by IWR-1 treatment. Thus, we treated the 143b-DxR and 143b-wt cell lines with IWR-1 for 16 h prior to addition of dox for 24 h. We found that the addition of IWR-1 as a sensitizer, in combination with dox, significantly reduced the viability of the 143b-DxR cells, compared to dox alone (Fig. 3A) . In the 143b-wt cells, we did not observe any significant reduction in dox IC 50 with the addition of IWR-1 sensitization (Fig. 3B) , findings which were consistent with the lack of effect on Calcein AM retention or dox retention in the 143b-wt cells. IWR-1 treatment alone inhibited cell viability in both the 143b-wt and 143b-DxR cell lines (Fig. 3C) . Sensitization by IWR-1 reduced the IC 50 of dox to 55.2% (11.76 µM, down from 21.31 µM) compared to dox alone in the 143b-DxR cells (Table 2) , while there was no significant difference in dox IC 50 between the IWR-1 sensitized and vehicle treated 143b-wt cells.
To determine whether this sensitization effect was due to increased dox toxicity or to IWR-1 toxicity, we further explored the functional effects of IWR-1 in combination with dox. Treatment with IWR-1 alone Inlaid graphs demonstrate cell distribution with averages and standard deviations (parenthesis) as indicated. Statistical significance was determined using two-way ANOVA corrected for multiple comparisons.
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did not induce any detectable disruption in the cell cycle distribution of 143b-DxR, or 143b-wt cells (Figs. 4A-B and 5A-B, respectively). We observed a significant increase (1.48-fold greater than vehicle control, p < 0.05) in G2/M cells with dox treatment at 1 µM in the 143b-DxR cell line (Fig. 4C) . Addition of IWR-1 as a sensitizer, 16 h prior to dox treatment, induced a statistically significant increase in G2/M cells (1.50-fold greater, p < 0.0001) relative to dox alone (Fig. 4C-D) . In the 143b-wt cell line, 20 nM dox induced cells accumulating at the G2/M checkpoint as well (Fig. 5C, 1 .72-fold increase relative to vehicle control, p < 0.05), yet 143b-wt cells which were sensitized with IWR-1 did not display any further G2/M phase cells from dox treatment, compared to the dox treated cells (Fig. 5C-D) . A hallmark of dox activity in the cell is the induction of DNA doublestranded breaks (DSBs). Thus, we studied the ability of dox, and the combination of IWR-1 and dox, to induce DNA damage in the cells, by analysis of γH2AX foci formation. Treatment with IWR-1 did not induce γH2AX foci formation relative to vehicle control in the 143b-DxR or 143b-wt cells (Figs. 6 and 7) . Dox treatment for 1 h induced γH2AX foci in the 143b-DxR (20 µM dox) and 143b-wt (1µM dox) cell lines, with mean foci-positive cells reaching 23.15%, and 21.94% of total cells, respectively (Figs. 6A, 7A ). An increase in γH2AX positive cells was observed (1.89-fold increase, relative to dox alone, p < 0.005) when 143b-DxR cells were sensitized with IWR-1 prior to treatment with dox ( Fig. 6A-B) . IWR-1 sensitization prior to dox treatment in the 143b-wt cell line did not induce a significant increase in foci-positive cells (Fig. 7A-B) . This indicated that dox toxicity due to DSBs was increased by IWR-1 in the 143b-DxR cell line, with no effect on the 143b-wt cells.
Discussion
Osteosarcoma patients suffer a striking reduction in 5-year event free survival if neoadjuvant chemotherapy is ineffective [5] . Resistance to many cancer chemotherapies is driven by the efflux activity of the family of ATP-dependent transporters [20] . Among cohorts of osteosarcoma patients, tumor expression of MDR-1 (P-gp) is an adverse prognostic factor which is significantly associated with poor outcomes [21, 22] . Thus, means to reduce expression or activity of the ABC transporters are of great interest for the improvement of cancer chemotherapy efficacy among osteosarcoma patients. In this study, we demonstrate that IWR-1 reduces efflux of doxorubicin and Calcein AM in doxorubicin-resistant osteosarcoma cells, and sensitizes these cells to doxorubicin by inhibiting their ability to remove doxorubicin; thus 
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increasing the effect of doxorubicin on cell cycle disruption and DNA damage. Canonical Wnt signaling is regulated by the Tankyrase 1 and Tankyrase 2 enzymes (Tnks1/2) through post-translational modification of Axin2 with poly-ADP-ribose (PAR). Axin2 acts as a scaffold that facilitates the assembly of a protein complex which targets β-catenin, the main effector of canonical Wnt signaling, for destruction. Thus, inhibition of Tnks1/2 activity results in stabilized Axin2, and reduced β-catenin-mediated Wnt signaling. Small molecule inhibitors of Tnks1/ 2 have been shown to regulate Wnt signaling and tumor growth in models of colorectal, breast, and non-small cell lung cancers [23] [24] [25] . Studies which have utilized the Tnks1/2 inhibitor IWR-1 in cancers have observed strong tumor suppressing activity, while our data demonstrate only weak effects on cell viability as a single-agent therapy in osteosarcoma cells (Fig. 2) [26, 27] . The IWR-1 molecule demonstrates endo/exo isomerism, where the -exo compound has been shown to be inactive, in contrast to the -endo compound (utilized exclusively in this study) which strongly regulates Wnt signaling both in vitro and in vivo [28] . While Tnks1/2 inhibitors are being considered as candidate molecules for primary chemotherapy, their application as adjuvant therapy may have an even greater impact. Combination therapy with Wntblocking compounds has been evaluated in the context of radiation therapy, EGFR inhibitors, and PI3K inhibitors [13, 16, 25, 29] . While these studies have focused on Wnt influence on the DNA damage response, or genome wide screens for efficacious targets, our study is the first to concentrate on the ability of a Tnks1/2 inhibiting small molecule to influence chemotherapy resistance through direct inhibition of cellular efflux. Due to the large number of cancer chemotherapy molecules which are substrates of ABC transporters, and the widespread reports of ABC family transporter overexpression in drug-resistant cancers, our results indicate that IWR-1 mediated inhibition of cellular efflux may well sensitize to a large number of molecules in resistant tumor models.
We chose to work primarily with the 5 µM concentration of IWR-1 for several reasons which are supported by the current literature. In their seminal paper, Huang et al. report the IC 50 for IWR-1 in targeting the Tnks1/2 enzymes, as well as the PARP1, and PARP2 enzymes which are structurally similar to Tnks1/2 in their catalytic ADP-ribose transferase domain [30] . While IWR-1 selectively inhibits Tnks1 and Tnks2 at concentrations of 131 nM and 56 nM, respectively, the PARP1 and PARP2 enzymes are targeted by IWR-1 at concentrations greater than 18.75 µM. Thus, treatment concentrations of IWR-1 which reach greater than 18.75 µM risk significant inhibition of PARP1 and PARP2, confounding conclusions which may be made regarding the specificity of the effects induced by IWR-1. Published reports show treatment concentrations of IWR-1 ranging from 10 nM to 50 µM, with several studies reporting effects on Wnt signaling and sensitization in the range of 5-20 µM [25, 27, 30, 31] . Indeed, a recent report demonstrated that 10 µM IWR-1 strongly inhibited both Tnks1 and Tnks2 with no effect on PARP1 and only weak effects on nine additional PARP enzymes [32] . Moreover, our data demonstrate that IWR-1 significantly increased Calcein AM accumulation in the cell at a concentration of 5 µM (508% increase -Fig. 1A) . Thus, we chose to continue with the sensitization experiments at the 5 µM concentration of IWR-1 based upon the limited likelihood of unintended effects on PARP1/2, consistency with adjacent reports, and data which we have reported in this manuscript.
Further investigations with patient-derived osteosarcoma tissues, and testing in additional resistant cell lines and animal models will more thoroughly establish IWR-1 and other Tnks1/2 inhibitors as chemotherapy sensitizing agents. Our data clearly demonstrate that IWR-1 inhibits cellular efflux of doxorubicin, and suggest that this inhibition is independent of Wnt signaling responses, as Axin2 and MDR-1 mRNA expression remained unchanged. While our data indicate inhibition of cellular efflux with effects only on a chemotherapy resistant cell line, this effect may be mediated through a number of possible mechanisms which are currently unclear. Further research might elucidate whether IWR-1 directly interacts with an ABC transporter to competitively inhibit its activity, and if so, which transporters are inhibited by IWR-1. Conversely, IWR-1 may act to reduce efflux of doxorubicin and Calcein AM through other mechanisms, such as by affecting proper trafficking of the ABC transporters through the cell, or by blocking their ability to embed within the cell membrane. Additional research using Tnks1/2 targeting drugs and genetic interference have demonstrated consistent and strong sensitization through adjacent, Wnt-intersecting pathways [14, 16, 25] . Thus, while our study uncovers inhibition of cellular efflux activity as an effect of IWR-1 treatment, sensitization to chemotherapeutic agents, such as doxorubicin, by IWR-1 may be driven through multiple pathways. The doxorubicin-resistant cell line which we have developed is a single clone of a resistant cell line. Thus, it likely represents a small subset of doxorubicin resistant osteosarcoma, limiting the conclusions which may be drawn regarding osteosarcoma treatment from the findings in this study. Models of resistance to methotrexate and cisplatin, as well as additional models of doxorubicin resistance in osteosarcoma will facilitate further validation of current findings and broader interpretation of conclusions regarding response to chemotherapies such as IWR-1 in the context of osteosarcoma treatment.
In sum, this report uncovers the doxorubicin sensitization effects of IWR-1 in chemotherapy resistant osteosarcoma. Highly potent and specific targeting of Tnks1/2 continues to demonstrate success as adjuvant chemotherapy in multiple models of cancers, the characterization and improved design of these candidate drugs is imperative for their progress towards the clinic. The use of sensitizing agents in osteosarcoma could make a significant positive impact in outcomes among the population of chemotherapy non-responsive osteosarcoma patients.
